For the first time in the long history of heart failure research, a treatment has not merely slowed the disease's advance but reversed it — restoring structure and function to hearts that medicine had previously learned only to manage. Scientists at the University of Utah delivered a missing protein back to damaged cardiac cells through a modified virus, and the hearts of four severely ill pigs responded by rebuilding themselves over six months. The finding, modest in its animal-trial scale, carries an outsized weight: it suggests that the boundary between decline and recovery in heart disease
Gene therapy reverses heart failure in pig trials, showing 30% improvement
In the history of heart failure research, we have not seen efficacy like this.
Mark
Why does the cBIN1 protein matter so much? What does it actually do in a healthy heart?
Mimi
It's about the mechanics of contraction. When cBIN1 is present in sufficient amounts, it helps organize the proteins inside heart cells so they can work together efficiently—like a well-drilled team. Without it, that coordination breaks down, and the heart can't squeeze with the force it needs to pump blood effectively.
Mark
So you're essentially replacing something that was lost. But why does heart failure cause cBIN1 to drop in the first place?
Mimi
That's still not entirely clear. What we know is that in failing hearts, the protein is depleted. Whether the disease causes the depletion or the depletion contributes to the disease is still being worked out. But the researchers noticed the pattern and asked the obvious question: what if we restore it?
Mark
The pigs showed 30 percent improvement. That's a big number. But they didn't fully recover, did they?
Mimi
No. The hearts got substantially better, but they didn't return to completely normal function. Still, the fact that they improved at all—while still under stress—is what shocked the field. Previous treatments just slow decline. This one reversed it.
Mark
What happens next? How do you go from four pigs to six million Americans?
Mimi
Carefully. They'll design a clinical trial, probably starting with a small group of heart failure patients, to see if the therapy works in humans the way it worked in pigs. The FDA has to approve the trial design first. If it works, you'd eventually have a treatment option where there really wasn't one before.
Mark
Is there any reason to think it might not work in humans?
Mimi
Pigs are a good model, but they're not humans. Human hearts are more complex, and people have other conditions and medications that could interact with the therapy. That's what the trials are for—to find out what actually happens when you try this in real patients.
Le Pouls
- Heart failure affects over six million Americans and has long been treated as a condition to slow, not reverse — making this result a direct challenge to a foundational assumption of cardiac medicine.
- Four pigs with severe cardiac damage not only survived a six-month period in which such animals typically die within weeks, but their hearts measurably rebuilt themselves.
- The therapy achieved a 30% improvement in pumping function — three to six times better than the best conventional treatments — and triggered reverse remodeling, the heart physically reshaping toward health.
- The mechanism is precise: a hollowed-out virus carries a copy of the cBIN1 gene into cardiac cells, prompting the body to produce a protein it had lost and desperately needed.
- Researchers and their pharmaceutical partner TikkunLev Therapeutics are targeting an FDA clinical trial application by fall 2025, with millions of patients as the potential horizon.
For the first time in the long history of heart failure research, a treatment has not merely slowed the disease's advance but reversed it — restoring structure and function to hearts that medicine had previously learned only to manage. Scientists at the University of Utah delivered a missing protein back to damaged cardiac cells through a modified virus, and the hearts of four severely ill pigs responded by rebuilding themselves over six months. The finding, modest in its animal-trial scale, carries an outsized weight: it suggests that the boundary between decline and recovery in heart disease may not be as fixed as medicine has long assumed.
Four pigs with failing hearts survived a full six months in a University of Utah laboratory — a period during which animals with their level of cardiac damage typically die within weeks. What kept them alive was an experimental gene therapy that researchers say has done something never before observed: it actually reversed the damage.
The treatment targets cBIN1, a protein essential to the heart's ability to contract with force. Long known to be depleted in heart failure patients with the worst outcomes, cBIN1 became the focus of a deceptively straightforward question: what if you simply gave it back? Researchers loaded a copy of the cBIN1 gene into a modified, disease-stripped virus and injected it into the pigs. The virus traveled to the heart, inserted the gene into cardiac cells, and the animals' own bodies began producing the missing protein.
The results surprised even the team. The hearts didn't just stabilize — they improved. Pumping function rose by 30% over six months, compared to the 5–10% gains offered by the best conventional treatments. The organs also underwent reverse remodeling, physically reshaping toward the structure of a healthy heart. Dr. Robin Shaw, who directed the research, said nothing like it had been seen in the entire history of heart failure study.
The study, published in npj Regenerative Medicine, used pigs deliberately — their hearts closely resemble human hearts in size and structure. With pharmaceutical partner TikkunLev Therapeutics, the team plans to apply for FDA approval to begin human clinical trials by fall 2025. For the more than six million Americans living with a condition that has offered no real path to recovery, the distance between animal trial and human hope has rarely felt shorter.
Four pigs with failing hearts walked out of the laboratory alive and stronger than when they went in. All survived a full six months—a span during which animals with their level of cardiac damage typically die within weeks. What kept them alive was an experimental gene therapy that did something heart researchers say they have never seen before: it actually reversed the damage.
The treatment targets a protein called cardiac bridging integrator 1, or cBIN1. When this protein is depleted in the heart, the muscle loses its ability to contract with force. Doctors have long known that heart failure patients with low cBIN1 levels face worse outcomes. The logic seemed simple enough: what if you gave the protein back? Researchers at the University of Utah decided to find out.
They took a virus—hollowed out and stripped of its ability to cause disease—and loaded it with an extra copy of the cBIN1 gene. When injected into the pigs, the virus traveled through the bloodstream like a molecular delivery truck, reaching the heart and inserting the gene into cardiac cells. The pigs' own bodies then began producing more of the missing protein.
The results startled even the researchers. The pigs' hearts didn't just stabilize. They improved. The organ's ability to pump blood increased measurably over the six-month period. While the hearts never reached fully healthy function, they moved substantially closer to normal—a 30 percent improvement in key measures of cardiac performance. To put that in perspective, the best conventional heart failure treatments manage improvements of 5 to 10 percent. The treated hearts also regained much of the physical structure of a healthy organ, a process researchers call reverse remodeling: the heart literally began to look and function like it should.
Dr. Robin Shaw, who directed the research at the University of Utah's cardiovascular institute, described the magnitude of the shift in stark terms. In the entire history of heart failure research, he said, nothing like this has been seen. Dr. TingTing Hong, the study's co-senior researcher, echoed the sentiment: the difference between previous treatments and this one was night and day.
The work matters because heart failure affects more than six million Americans. It is a condition that typically worsens over time, and while medications can slow the decline, they rarely reverse it. The idea that a single treatment could restore function to a damaged heart—not just halt its deterioration but actually repair it—represents a fundamental shift in what researchers thought was possible.
The study, published this week in the journal npj Regenerative Medicine, was conducted in pigs for good reason. Their hearts are similar in size and structure to human hearts, making them a reliable model for understanding how a treatment might work in people. The next step is to move toward human trials. The research team, working with the pharmaceutical company TikkunLev Therapeutics, plans to submit an application to the FDA for permission to begin clinical trials by fall 2025. If those trials succeed, the therapy could eventually reach the millions of Americans living with a condition that has, until now, offered no real path to recovery.
Citations marquantes
In the history of heart failure research, we have not seen efficacy like this. It's night and day.— Dr. Robin Shaw, director of the Nora Eccles Harrison Cardiovascular Research and Training Institute at the University of Utah
This human disease, which affects more than six million Americans—maybe this is something we can cure.— Dr. TingTing Hong, associate professor of pharmacology and toxicology at the University of Utah
Envie de l'histoire complète ?
Lire l'original sur UPI News ↗
Education